{"type":"trials","record":{"id":41874,"source_id":"clinicaltrials-gov","external_id":"NCT05266495","title":"Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting","brief_summary":"The study is a prospective and retrospective, observational, single-arm, non-randomized cohort study of ocular treatment with intravitreal injections of brolucizumab in nAMD patients. This study will be conducted prospectively and retrospectively (for patients who had their first brolucizumab injection before study start) using data collected in a standardized manner.","overall_status":"Terminated","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Novartis Pharmaceuticals","enrollment":3,"countries":["United Arab Emirates"],"start_date":"2022-04-13","completion_date":"2023-03-13","last_update_date":"2025-01-13","source_url":"https://clinicaltrials.gov/study/NCT05266495","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years to 100 Years","comparator":null,"organization":"Novartis","interventions":["Brolucizumab"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Percentage of patients with absence of SRF and IRF — Month 12","Percentage of patients ≥ 80 years old — Baseline","Duration of diagnosis — Baseline","Percentage of patients with baseline visit — Baseline","Percentage of patients with bilateral disease — Baseline","Percentage of patients with lesion type — Baseline","Percentage of patients with presence of SRF, IRF and sub-RPE — Baseline","Baseline CST — Baseline, Month 3, Month 6, Month 9 and Month 12","Baseline VA — Baseline","Percentage of patients with the study eye that has VA equal or less than the VA in fellow eye — Baseline","Percentage of patients with baseline VA in the following categories (≤35, 36-69, ≥ 70 ETDRS letters) — Baseline","Percentage of patients with VA between 34 and 72 ETDRS letters — Baseline","Percentage of patients with baseline VA < 73 ETDRS letters and active (SRF only) — Baseline","Percentage of patients with different ethnic groups — Baseline","Switch Patients: Previous anti-VEGF treatments of nAMD pre-treated patients — Baseline","Switch Patients: Duration of previous anti-VEGF treatments — Baseline","Switch Patients: Number of injections in the last year before switching to brolucizumab — Baseline","Switch Patients: Last interval of anti-VEGF treatment before switching — Baseline","Percentage of patients with absence of SRF — Month 3, Month 6, Month 9 and Month 12","Percentage of patients with stable SRF — Month 3, Month 6, Month 9 and Month 12"],"design_description":null,"source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","Brolucizumab"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05266495","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-04-13 to 2023-03-13","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years to 100 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.885Z","intervention":["Brolucizumab"],"participants":3,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Percentage of patients with absence of SRF and IRF — Month 12","Percentage of patients ≥ 80 years old — Baseline","Duration of diagnosis — Baseline","Percentage of patients with baseline visit — Baseline","Percentage of patients with bilateral disease — Baseline","Percentage of patients with lesion type — Baseline","Percentage of patients with presence of SRF, IRF and sub-RPE — Baseline","Baseline CST — Baseline, Month 3, Month 6, Month 9 and Month 12","Baseline VA — Baseline","Percentage of patients with the study eye that has VA equal or less than the VA in fellow eye — Baseline","Percentage of patients with baseline VA in the following categories (≤35, 36-69, ≥ 70 ETDRS letters) — Baseline","Percentage of patients with VA between 34 and 72 ETDRS letters — Baseline","Percentage of patients with baseline VA < 73 ETDRS letters and active (SRF only) — Baseline","Percentage of patients with different ethnic groups — Baseline","Switch Patients: Previous anti-VEGF treatments of nAMD pre-treated patients — Baseline","Switch Patients: Duration of previous anti-VEGF treatments — Baseline","Switch Patients: Number of injections in the last year before switching to brolucizumab — Baseline","Switch Patients: Last interval of anti-VEGF treatment before switching — Baseline","Percentage of patients with absence of SRF — Month 3, Month 6, Month 9 and Month 12","Percentage of patients with stable SRF — Month 3, Month 6, Month 9 and Month 12"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41874","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}